Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in FSGS
NCT00001959Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Dec 1999
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in focal segmental glomerulosclerosis (FSGS), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Decrease in Glomerular Filtration Rate at 12 months. Started Dec 1999; status: completed.
02
Drugs
pirfenidone
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT00001959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001959.